Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

Nature·Apr 16

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A phase 1 trial is underway to test the use of human embryonic stem cell-derived dopaminergic neurons in treating Parkinson's disease. Some outlets report that high-dose stem cell treatment may be trending towards improvement, while others note that cell therapies have been found to be safe in clinical trials. The outcomes of these trials are not yet fully clear, but preliminary data on stem cell therapy for Parkinson's disease appears promising.

Full coverage

Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

Nature·Jul 9

Dopamine Cell Replacement Therapy: A New Frontier in Parkinson Disease Treatment

Neurology Advisor·May 19

High-Dose Stem Cell Treatment for Parkinson’s Disease Trends Toward Improvement

Neurology Today·Apr 20

Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats

Nature·May 26

Human pluripotent stem cell engineering with CRISPR–Cas9 for Parkinson’s disease

Nature·Apr 10

Parkinson’s Cell Therapies Are Safe in Two Clinical Trials

Inside Precision Medicine·Apr 18

Promising New Data on Stem Cell Therapy for Parkinson’s

Medscape·Apr 17

Human stem cell-derived neurons establish functional inhibitory–excitatory cortical circuits in a chimeric transplantation model | Scientific Reports

Nature·Mar 4

View original report at Nature ↗

Fetching the latest headlines…